At Auspherix we are developing compounds to target unmet medical needs that arise from serious and life-threatening bacterial infections including drug-resistant hospital infections.
Since Auspherix organogold compounds have broad-spectrum Gram-negative activity they have the potential to address the greatest unmet medical need in the clinic, including life-threatening multi-drug resistant infections.
The recent tranche of launched antibacterial medicines are based on established mechanisms and are generally viewed as incremental advances. It is now widely recognised that novel classes of antibiotics such as that being developed by Auspherix, are going to be required to address the rising challenge of antimicrobial resistance (AMR).
Our partnering opportunities
Whilst Auspherix is committed to progressing its pipeline of organogold compounds into clinical development, it welcomes strategic partnering opportunities with pharma and biotech companies in the anti-infectives space to expand its R&D capabilities and pipeline.
At an appropriate stage, the Company’s strategy is to license its novel antibiotic drug candidate molecules to a partner with the expertise in later stage development and commercialisation in the anti-infective space to ensure that its innovations have the optimal chance of making a difference to patients, as quickly as possible.